HAI
PRTK

Hennessy Advisors Inc’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Hennessy Advisors Inc’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-25,490
Closed -$331K – 341
2018
Q1 		$331K Buy
+25,490
New +$380K 0.01% 336

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
APCM
Arbiter Partners Capital Management New York $175M AUM 99.81% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Hennessy Advisors Inc's PRTK Position: Q2 2018 in Review

Hennessy Advisors Inc sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q2 2018, closing a stake of 25,490 shares — an estimated $331K sold.

Hennessy Advisors Inc first reported a position in PRTK in Q1 2018 and held it in 1 quarter. The position peaked at $331K in Q1 2018. 110 funds tracked by Wall St. Rank hold PRTK as of Q2 2018.

  • Hennessy Advisors Inc reported no remaining Paratek Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
  • Hennessy Advisors Inc sold 25,490 Paratek Pharmaceuticals, Inc. shares in Q2 2018, an estimated $331K.
  • Hennessy Advisors Inc first reported a position in Paratek Pharmaceuticals, Inc. in Q1 2018 and held it in 1 quarter.
  • Hennessy Advisors Inc's Paratek Pharmaceuticals, Inc. position peaked at $331K in Q1 2018.
  • 110 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q2 2018.

Based on Hennessy Advisors Inc's 13F filing for Q2 2018, filed 20 Jul 2018.